AACR: GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) Drives NK Cell Activation and ADCC against Head and Neck Squamous Cell Carcinomas April 9, 2022
EBMT: A Tri-specific Killer Engager (TriKE®) against B7-H3 enhances NK cell mediated killing of multiple myeloma March 22, 2022
ESMO Targeted Anticancer Therapies Congress: Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using Tri-specific Killer Engager (TriKE®) March 9, 2022
ESMO I/O: Novel B7-H3 Targeting Dual Nanobody NK Cell Engagers Display Robust Activity Against a Broad Spectrum of Solid and Hematologic Malignancies. December 8, 2021
